Reply: P2Y12 Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent. Angiolillo DJ, Baber U, Dangas GD, Mehran R, et al. J Am Coll Cardiol 2020;76:1274-1275.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Angiolillo DJ, Baber U, Dangas GD, Mehran R, et al. Reply: P2Y12 Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent. J Am Coll Cardiol 2020;76:1274-1275.
PMID: 32883424